2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T45d,Of 26 eligible trials, 25 had available HiSCR-50 data, including 5767 total patients and 39 unique treatments. Compared with placebo, the following treatments were associated with significantly higher HiSCR-50 response rates: sonelokimab, 120 mg, every 4 weeks; lutikizumab, 300 mg, every 2 weeks; adalimumab, 40 mg, once per week; sonelokimab, 240 mg, every 2 weeks; bimekizumab, 320 mg, every 2 weeks; povorcitinib, 15 mg, once per day; bimekizumab, 320 mg, every 4 weeks; secukinumab, 300 mg, every 4 weeks; and secukinumab, 300 mg, every 2 weeks. Most differences between adalimumab, 40 mg, once per week, and other targeted treatments were not statistically significant. The percentage of patients experiencing SAEs ranged from 0% to 10% in the placebo groups, 0% to 8% in the adalimumab (40 mg, once per week) groups, and 0% to 6% in the other active treatment groups. The percentage of patients discontinuing treatment due to adverse events ranged from 0% to 10% in the placebo groups, 0% to 4% in the adalimumab (40 mg, once per week) groups, and 0% to 15% (ropsacitinib) in the other active treatment groups.31:T9f1,There is limited comparative information on regulatory approved and pipeline treatments in hidradenitis suppurativa (HS). To compare efficacy, safety, and tolerability of treatments for moderate to severe HS. MEDLINE, Embase, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials were searched from inception to June 28, 2024. Phase 2 and 3 randomized clinical trials of medical interventions (cytokine inhibitors, small molecule inhibitors, cell inhibitors, and other novel immune or inflammatory modifiers) for adults with moderate to severe HS having primary efficacy assessments between 12 and 16 weeks. Data extraction and risk of bias assessments were performed independently by 2 reviewers. Efficacy outcomes were analyzed using random-effects network meta-analysis. Safety and tolerability outcomes were analyzed using pairwise fixed-effect meta-analyses vs placebo. Data analysis was performed between August 22, 2024, and April 7, 2025. Primary efficacy, safety, and tolerability outcomes were Hidradenitis Suppurativa Clinical Response (HiSCR)-50, occurrence of serious adverse events (SAEs), and treatment discontinuation due to adverse events, respectively. HiSCR-75 was a secondary efficacy outcome. Of 26 eligible trials, 25 had available HiSCR-50 data, including 5767 total patients and 39 unique treatments. Compared with placebo, the following treatments were associated with significantly higher HiSCR-50 response rates: sonelokimab, 120 mg, every 4 weeks; lutikizumab, 300 mg, every 2 weeks; adalimumab, 40 mg, once per week; sonelokimab, 240 mg, every 2 weeks; bimekizumab, 320 mg, every 2 weeks; povorcitinib, 15 mg, once per day; bimekizumab, 320 mg, every 4 weeks; secukinumab, 300 mg, every 4 weeks; and secukinumab, 300 mg, every 2 weeks. Most differences between adalimumab, 40 mg, once per week, and other targeted treatments were not statistically significant. The percentage of patients experiencing SAEs ranged from 0% to 10% in the placebo groups, 0% to 8% in the adalimumab (40 mg, once per week) groups, and 0% to 6% in the other active treatment groups. The percentage of patients discontinuing treatment due to adverse events ranged from 0% to 10% in the placebo groups, 0% to 4% in the adalimumab (40 mg, once per week) groups, and 0% to 15% (ropsacitinib) in the other active treatment groups. This network meta-analysis provides evidence for the comparative efficacy and safety of currently approved and pipeline medications for moderate to severe HS in the absence of head-to-head trials.32:Td09,ImportanceThere is limited comparative information on regulatory approved and pipeline treatments in hidradenitis suppurativa (HS).ObjectiveTo compare efficacy, safety, and tolerability of treatments for moderate to severe HS.Data SourcesMEDLINE, Embase, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials were searched from inception to June 28, 2024.Study SelectionPhase 2 and 3 randomized clinical trials of medical interventions (cytokine inhibitors, small molecule inhibitors, cell inhibitors, and other novel immune or inflammatory modifiers) for adults with moderate to severe HS having primary efficacy assessments between 12 and 16 weeks.Data Extraction and SynthesisData extraction and risk of bias assessments were performed independently by 2 reviewers. Efficacy outcomes were analyzed using random-effects network meta-analysis. Safety and tolerability outcomes were analyzed using pairwise fixed-effect meta-analyses vs placebo. Data analysis was performed between August 22, 2024, and April 7, 2025.Main Outcomes and MeasuresPrimary efficacy, safety, and tolerability outcomes were Hidradenitis Suppurativa Clinical Response (HiSCR)-50, occurrence of serious adverse events (SAEs), and treatment discontinuation due to adverse events, respectively. HiSCR-75 was a secondary efficacy outcome.ResultsOf 26 eligible trials, 25 had available HiSCR-50 data, including 5767 total patients and 39 unique treatments. Compared with placebo, the following treatments were associated with significantly higher HiSCR-50 response rates: sonelokimab, 120 mg, every 4 weeks; lutikizumab, 300 mg, every 2 weeks; adalimumab, 40 mg, once per week; sonelokimab, 240 mg, every 2 weeks; bimekizumab, 320 mg, every 2 weeks; povorcitinib, 15 mg, once per day; bimekizumab, 320 mg, every 4 weeks; secukinumab, 300 mg, every 4 weeks; and secukinumab, 300 mg, every 2 weeks. Most differences between adalimumab, 40 mg, once per week, and other targeted treatments were not statistically significant. The percentage of patients experiencing SAEs ranged from 0% to 10% in the placebo groups, 0% to 8% in the adalimumab (40 mg, once per week) groups, and 0% to 6% in the other active treatment groups. The percentage of patients discontinuing treatment due to adverse events ranged from 0% to 10% in the placebo groups, 0% to 4% in the adalimumab (40 mg, once per week) groups, and 0% to 15% (ropsacitinib) in the other active treatment groups.Conclusions and RelevanceThis network meta-analysis provides evidence for the comparative efficacy and safety of currently approved and pipeline medications for moderate to severe HS in the absence of head-to-head trials.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Systematic Review and Network Meta-analysis: study design Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Systematic Review and Network Meta-analysis (study design). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/study_design/Systematic%20Review%20and%20Network%20Meta-analysis\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Study Designs\",\"item\":\"https://www.reachrx.ai/hub/tag/study_design\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Systematic Review and Network Meta-analysis\",\"item\":\"https://www.reachrx.ai/hub/tag/study_design/Systematic%20Review%20and%20Network%20Meta-analysis\"}]}}"}}]],["$","$L2f",null,{"title":"Systematic Review and Network Meta-analysis: Research & Clinical Takeaways","description":"Browse Systematic Review and Network Meta-analysis research papers with clear, practical takeaways for your clinical practice.","papers":[{"doi":"10.1001/jamadermatol.2025.1976","pmid":"40601333","title":"Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-07-02T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.1976","source_score":113,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-09-21","doi":"10.1001/jamadermatol.2025.1976","days":"30","issn":"2168-6068","rank":"6","field":"Clinical Medicine","score":"113","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.1976","title":"Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa: A Living Systematic Review and Network Meta-Analysis.","journal":"JAMA dermatology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"40601333","conclusions":"","publication_date":"2025-07-02T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.1976","URL":"https://doi.org/10.1001/jamadermatol.2025.1976","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2835830/jamadermatology_garg_2025_oi_250030_1757438048.48017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"931","type":"journal-article","issue":"9","score":1,"title":["Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa"],"author":[{"given":"Amit","family":"Garg","sequence":"first","affiliation":[{"name":"Northwell, New Hyde Park, New York"},{"name":"Department of Dermatology, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York"}]},{"given":"Erica","family":"Cohn","sequence":"additional","affiliation":[{"name":"Northwell, New Hyde Park, New York"},{"name":"Department of Dermatology, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York"}]},{"given":"Bria","family":"Midgette","sequence":"additional","affiliation":[{"name":"Northwell, New Hyde Park, New York"},{"name":"Department of Dermatology, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York"}]},{"given":"Kelly","family":"Frasier","sequence":"additional","affiliation":[{"name":"Northwell, New Hyde Park, New York"},{"name":"Department of Dermatology, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York"}]},{"given":"Andrew","family":"Strunk","sequence":"additional","affiliation":[{"name":"Northwell, New Hyde Park, New York"}]}],"issued":{"date-parts":[[2025,9,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"161","created":{"date-time":"2025-07-02T11:00:34Z","timestamp":1751454034000,"date-parts":[[2025,7,2]]},"indexed":{"date-time":"2025-10-18T21:05:07Z","timestamp":1760821507414,"date-parts":[[2025,10,18]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2835830"}},"subtitle":["A Living Systematic Review and Network Meta-Analysis"],"deposited":{"date-time":"2025-09-17T15:00:47Z","timestamp":1758121247000,"date-parts":[[2025,9,17]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,9,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1016/j.jaad.2019.06.1301","key":"doi250030r1","year":"2020","issue":"2","author":"Garg","volume":"82","first-page":"366","unstructured":null,"article-title":"Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.21798","key":"doi250030r2","year":"2022","issue":"6","author":"Midgette","volume":"187","first-page":"927","unstructured":null,"article-title":"Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMoa1504370","key":"doi250030r3","year":"2016","issue":"5","author":"Kimball","volume":"375","first-page":"422","unstructured":null,"article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa.","journal-title":"N Engl J Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)00022-3","key":"doi250030r4","year":"2023","issue":"10378","author":"Kimball","volume":"401","first-page":"747","unstructured":null,"article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(24)00101-6","key":"doi250030r5","year":"2024","issue":"10443","author":"Kimball","volume":"403","first-page":"2504","unstructured":null,"article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.","journal-title":"Lancet","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2019.02.068","key":"doi250030r6","year":"2019","issue":"1","author":"Alikhan","volume":"81","first-page":"91","unstructured":null,"article-title":"North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17537","key":"doi250030r7","year":"2019","issue":"5","author":"Ingram","volume":"180","first-page":"1009","unstructured":null,"article-title":"British Association of Dermatologists guidelines for the management of hidradenitis suppurativa (acne inversa) 2018.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.12966","key":"doi250030r8","year":"2015","issue":"4","author":"Zouboulis","volume":"29","first-page":"619","unstructured":null,"article-title":"European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.20472","key":"doi250030r9","year":"2025","issue":"5","author":"Zouboulis","volume":"39","first-page":"899","unstructured":null,"article-title":"European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.f2914","key":"doi250030r11","year":"2013","issue":null,"author":"Mills","volume":"346","first-page":"f2914","unstructured":null,"article-title":"Demystifying trial networks and network meta-analysis.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.l4898","key":"doi250030r12","year":"2019","issue":null,"author":"Sterne","volume":"366","first-page":"l4898","unstructured":null,"article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.18637/jss.v106.i02","key":"doi250030r13","year":"2023","issue":"2","author":"Balduzzi","volume":"106","first-page":null,"unstructured":null,"article-title":"Netmeta: an R package for network meta-analysis using frequentist methods.","journal-title":"J Stat Softw","doi-asserted-by":"publisher"},{"DOI":"10.1002/jrsm.1058","key":"doi250030r14","year":"2012","issue":"4","author":"Rücker","volume":"3","first-page":"312","unstructured":null,"article-title":"Network meta-analysis, electrical networks and graph theory.","journal-title":"Res Synth Methods","doi-asserted-by":"publisher"},{"DOI":"10.1002/sim.6236","key":"doi250030r15","year":"2014","issue":"25","author":"Rücker","volume":"33","first-page":"4353","unstructured":null,"article-title":"Reduce dimension or reduce weights? comparing two approaches to multi-arm studies in network meta-analysis.","journal-title":"Stat Med","doi-asserted-by":"publisher"},{"DOI":"10.1186/s12874-015-0060-8","key":"doi250030r19","year":"2015","issue":"1","author":"Rücker","volume":"15","first-page":"58","unstructured":null,"article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods.","journal-title":"BMC Med Res Methodol","doi-asserted-by":"publisher"},{"DOI":"10.1002/jrsm.1044","key":"doi250030r20","year":"2012","issue":"2","author":"Higgins","volume":"3","first-page":"98","unstructured":null,"article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies.","journal-title":"Res Synth Methods","doi-asserted-by":"publisher"},{"DOI":"10.1186/1471-2288-13-35","key":"doi250030r21","year":"2013","issue":null,"author":"Krahn","volume":"13","first-page":"35","unstructured":null,"article-title":"A graphical tool for locating inconsistency in network meta-analyses.","journal-title":"BMC Med Res Methodol","doi-asserted-by":"publisher"},{"DOI":"10.1002/sim.3767","key":"doi250030r22","year":"2010","issue":"7-8","author":"Dias","volume":"29","first-page":"932","unstructured":null,"article-title":"Checking consistency in mixed treatment comparison meta-analysis.","journal-title":"Stat Med","doi-asserted-by":"publisher"},{"DOI":"10.1002/jrsm.57","key":"doi250030r23","year":"2012","issue":"2","author":"Chaimani","volume":"3","first-page":"161","unstructured":null,"article-title":"Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions.","journal-title":"Res Synth Methods","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pmed.1003082","key":"doi250030r24","year":"2020","issue":"4","author":"Nikolakopoulou","volume":"17","first-page":null,"unstructured":null,"article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis.","journal-title":"PLoS Med","doi-asserted-by":"publisher"},{"DOI":"10.1002/cl2.1080","key":"doi250030r25","year":"2020","issue":"1","author":"Papakonstantinou","volume":"16","first-page":null,"unstructured":null,"article-title":"CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis.","journal-title":"Campbell Syst Rev","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2021.2905","key":"doi250030r27","year":"2021","issue":"11","author":"Glatt","volume":"157","first-page":"1279","unstructured":null,"article-title":"Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.7326/0003-4819-157-12-201212180-00004","key":"doi250030r29","year":"2012","issue":"12","author":"Kimball","volume":"157","first-page":"846","unstructured":null,"article-title":"Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.","journal-title":"Ann Intern Med","doi-asserted-by":"publisher"},{"DOI":"10.1111/exd.14619","key":"doi250030r30","year":"2022","issue":"10","author":"Kimball","volume":"31","first-page":"1522","unstructured":null,"article-title":"IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.","journal-title":"Exp Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.19252","key":"doi250030r31","year":"2023","issue":"10","author":"Kimball","volume":"37","first-page":"2098","unstructured":null,"article-title":"Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: a phase 2 randomized study.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-023-00913-3","key":"doi250030r32","year":"2023","issue":"5","author":"Kimball","volume":"13","first-page":"1099","unstructured":null,"article-title":"Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial.","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1056/EVIDoa2300155","key":"doi250030r33","year":"2024","issue":"3","author":"Kimball","volume":"3","first-page":null,"unstructured":null,"article-title":"Brepocitinib, zimlovisertib, and ropsacitinib in hidradenitis suppurativa.","journal-title":"NEJM Evid","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2023.10.034","key":"doi250030r34","year":"2024","issue":"3","author":"Kirby","volume":"90","first-page":"521","unstructured":null,"article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1093/bjd/ljae144","key":"doi250030r39","year":"2024","issue":"4","author":"Alavi","volume":"191","first-page":"508","unstructured":null,"article-title":"Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamasurg.2021.3655","key":"doi250030r43","year":"2021","issue":"11","author":"Bechara","volume":"156","first-page":"1001","unstructured":null,"article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS Randomized Clinical Trial.","journal-title":"JAMA Surg","doi-asserted-by":"publisher"},{"DOI":"10.1080/09546634.2021.1927949","key":"doi250030r45","year":"2022","issue":"4","author":"Gupta","volume":"33","first-page":"2149","unstructured":null,"article-title":"Efficacy of non-surgical monotherapies for hidradenitis suppurativa: a systematic review and network meta-analyses of randomized trials.","journal-title":"J Dermatolog Treat","doi-asserted-by":"publisher"},{"DOI":"10.3390/pharmaceutics15051351","key":"doi250030r46","year":"2023","issue":"5","author":"Tsai","volume":"15","first-page":"1351","unstructured":null,"article-title":"Efficacy and safety of biologics and small molecules for moderate-to-severe Hidradenitis Suppurativa: a systematic review and network meta-analysis.","journal-title":"Pharmaceutics","doi-asserted-by":"publisher"},{"DOI":"10.25259/IJDVL_665_2023","key":"doi250030r47","year":"2024","issue":null,"author":"Husein-ElAhmed","volume":null,"first-page":"1","unstructured":null,"article-title":"Comparative efficacy and therapeutic positioning of biologics in hidradenitis suppurativa: a systematic review with network meta-analysis of randomised trials.","journal-title":"Indian J Dermatol Venereol Leprol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jclinepi.2017.08.010","key":"doi250030r48","year":"2017","issue":null,"author":"Elliott","volume":"91","first-page":"23","unstructured":null,"article-title":"Living systematic review: 1. Introduction-the why, what, when, and how.","journal-title":"J Clin Epidemiol","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.311.7003.485","key":"doi250030r49","year":"1995","issue":"7003","author":"Altman","volume":"311","first-page":"485","unstructured":null,"article-title":"Absence of evidence is not evidence of absence.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1177/02683962221105904","key":"doi250030r50","year":"2022","issue":"3","author":"Amrhein","volume":"37","first-page":"316","unstructured":null,"article-title":"Discuss practical importance of results based on interval estimates and P value functions, not only on point estimates and null P values.","journal-title":"J Inf Technol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi250030r10","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"U.S. National Library of Medicine. ClinicalTrials.gov. Updated April 14, 2025. Accessed May 5, 2025. https://clinicaltrials.gov/search?cond=hidradenitis%20suppurativa&aggFilters=phase:2%203,status:rec,studyType:int","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Reich? K. Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa. ClinicalTrials.gov identifier: NCT05322473. Updated May 3, 2024. Accessed May 5, 2025. https://clinicaltrials.gov/study/NCT05322473","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r17","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"AbbVie Inc. Humira (adalimumab) [package insert]. U.S. Food and Drug Administration website. Updated November 2023. Accessed May 5, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125057s423lbl.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r18","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Humira (adalimumab) [SmPC]. European Medicines Agency website. Updated March 2025. Accessed April 14, 2025. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r26","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"ChemoCentryx Inc. Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA). ClinicalTrials.gov identifier: NCT03852472. Updated March 15, 2024. Accessed May 5, 2024. https://clinicaltrials.gov/study/NCT03852472","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r28","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Randazzo? B. A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa. ClinicalTrials.gov identifier: NCT04856930. Updated February 15, 2023. Accessed May 5, 2025. https://clinicaltrials.gov/study/NCT04856930","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r35","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Lee? RAK. Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa. ClinicalTrials.gov identifier: NCT01838499. Updated September 1, 2016. Accessed May 5, 2025. https://clinicaltrials.gov/study/NCT01838499","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r36","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Janssen Research & Development, LLC. A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa. ClinicalTrials.gov identifier: NCT04019041. Updated July 27, 2023. Accessed May 5, 2025. https://clinicaltrials.gov/study/NCT04019041","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r37","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"AbbVie. A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms. ClinicalTrials.gov identifier: NCT04430855. Updated February 6, 2023. Accessed May 5, 2025. https://clinicaltrials.gov/study/NCT04430855","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r38","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Eli Lilly and Co. A Study of LY3041658 in Adults With Hidradenitis Suppurativa. ClinicalTrials.gov identifier: NCT04493502. Updated April 28, 2023. Accessed May 5, 2025. https://clinicaltrials.gov/study/NCT04493502","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r40","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Janssen Research & Development, LLC. A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (LYRA). ClinicalTrials.gov identifier: NCT04988308. Updated November 13, 2023. Accessed May 5, 2025. https://clinicaltrials.gov/study/NCT04988308","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r41","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"AbbVie. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy. ClinicalTrials.gov identifier: NCT05139602. Updated October 30, 2024. Accessed May 5, 2025. https://clinicaltrials.gov/study/NCT05139602","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r42","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Betah? D. Hidradenitis Suppurativa Phase 2b Study of Izokibep. ClinicalTrials.gov identifier: NCT05355805. Updated September 25, 2024. Accessed May 5, 2025. https://clinicaltrials.gov/study/NCT05355805","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi250030r44","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Othmar? Z. Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (SHINE). ClinicalTrials.gov identifier: NCT03487276. Updated April 8, 2021. Accessed May 5, 2025. https://clinicaltrials.gov/study/NCT03487276","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2025,9,1]]},"reference-count":50,"published-online":null,"references-count":50,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamadermatol.2025.1976","is_oa":false,"title":"Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa","updated":"2025-08-04T14:10:34+00:00","published_date":"2025-07-02","best_oa_location":null}},"created_at":"2025-09-19T18:16:55.332Z","updated_at":"2025-10-21T07:06:57.272Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.1976","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.1976","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.1976","tag_type":"condition","value":"Hidradenitis Suppurativa","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.1976","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.1976","tag_type":"sample_size","value":"n=5767","value_numeric":5767},{"paper_doi":"10.1001/jamadermatol.2025.1976","tag_type":"study_design","value":"Systematic Review and Network Meta-analysis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.1976","tag_type":"warning","value":"Abstract reports significance without absolute response rates or effect sizes for each treatment.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.1976","tag_type":"warning","value":"Comparative efficacy is based on indirect evidence; no head-to-head trials were included.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.1976","tag_type":"warning","value":"Findings reflect only 12–16 week outcomes; long-term efficacy and safety are not addressed.","value_numeric":null}],"summaries":{"what_studied":"Systematic review and network meta-analysis of phase 2 and 3 randomized trials in adults with moderate to severe hidradenitis suppurativa, assessing 12–16 week efficacy (HiSCR-50 primary; HiSCR-75 secondary), safety (serious adverse events), and tolerability (discontinuations). It included 25 trials with HiSCR-50 data, 5767 patients, and 39 unique treatments.","key_result":"Compared with placebo, higher HiSCR-50 response was seen with sonelokimab (120 mg q4wk; 240 mg q2wk), lutikizumab (300 mg q2wk), adalimumab (40 mg weekly), bimekizumab (320 mg q2wk; 320 mg q4wk), povorcitinib (15 mg daily), and secukinumab (300 mg q4wk; 300 mg q2wk); most differences vs adalimumab 40 mg weekly were not statistically significant. SAEs occurred in 0%–10% of placebo groups, 0%–8% with adalimumab 40 mg weekly, and 0%–6% with other active treatments; discontinuations due to AEs were 0%–10% (placebo), 0%–4% (adalimumab 40 mg weekly), and 0%–15% with other actives (highest with ropsacitinib).","limitations":"Comparisons are indirect because head-to-head trials were absent. Outcomes reflect short-term assessments (12–16 weeks), and safety/tolerability were analyzed only in pairwise comparisons vs placebo.","practice_takeaway":"Several agents improved HiSCR-50 by 12–16 weeks vs placebo in adults with moderate to severe HS, with low SAE rates across groups; weekly adalimumab performed similarly to many targeted treatments. Use these short-term comparative data to guide initial systemic therapy choice while monitoring for discontinuations and AEs."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"study_design","value":"Systematic Review and Network Meta-analysis"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Study Designs","href":"/hub/tag/study_design"},{"name":"Systematic Review and Network Meta-analysis"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"study_design","hub_tag_value":"Systematic Review and Network Meta-analysis"}}}]]

Papers